BIONTECH
LIVE

Serial Number

79349208

Owner

BioNTech SE

Attorney

Monica Riva Talley

Filing Date

Dec 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BIONTECH Trademark

Serial Number: 79349208 • Registration: 7129110

BIONTECH is a trademark filed by BioNTech SE on December 28, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

BioNTech SE (46 trademarks)

An der Goldgrube 12

Entity Type: 94

Trademark Details

Filing Date

December 28, 2021

Registration Date

August 8, 2023

Published for Opposition

May 23, 2023

Goods & Services

Downloadable mobile applications for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable computer software for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable e-commerce computer software for enabling users to perform electronic business transactions via a global computer network

Pharmaceutical products for the prevention and treatment of cancer, infectious diseases, and immunological diseases, except vitamin preparations, mineral food supplements, probiotics, omega 3 preparations, dietetic substances and food supplements for medical and non-medical purposes; vaccines; chemical reagents used for medical purposes; biochemical reagents used for purposes for the treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; macromolecules, namely, nucleic acid sequences and proteins, used for medical and veterinary purposes; cell based immune therapeutics for treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; diagnostic preparations for clinical or medical laboratory use

Business advisory services in the field of electronic commerce; providing business information in the field of electronic commerce; providing business information, namely, customer information on pharmaceutical and medical products through an on-line computer network; wholesale and retail store services featuring pharmaceutical products, medicinal preparations, and medical supplies

Chemicals for use in pharmaceutical industry; active chemical ingredients for use in manufacture of anti-cancer drugs and vaccines; adjuvants for use in manufacture of vaccines; nucleic acids, proteins and peptides for laboratory use; diagnostic preparations for scientific or research use other than for medical purposes

Medical, hygienic and beauty care; health care; providing medical information to patients and healthcare professionals concerning pharmaceutical products, vaccines, medical products, medical diseases and disorders and related treatments via the Internet; gene and cell therapy; medical and psychological counselling services; medical services, namely, providing therapies for treating cancer, infectious diseases and immunological diseases; veterinary services, namely, providing therapies for treating cancer, infectious diseases, and immunological diseases; medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes

Medical diagnostic devices for analysis of body fluids and biopsies for diagnosis and monitoring of cancer, infectious diseases, and immunological diseases; medical diagnostic devices for analysis of body fluids and biopsies for patient stratification

Medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; medical and scientific research services by compiling data for clinical trials and drug admission

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 31, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 3, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 13, 2023 FICS
FINAL DISPOSITION PROCESSED
Nov 13, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 8, 2023 FICR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 25, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 25, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 25, 2023 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 8, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 8, 2023 R.PR
NOTIFICATION PROCESSED BY IB
May 24, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 23, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 23, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 3, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 3, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 3, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 18, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 18, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 18, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 18, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 18, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2023 TROA
REFUSAL PROCESSED BY IB
Jan 10, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 16, 2022 RFCS
REFUSAL PROCESSED BY MPU
Dec 16, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 5, 2022 RFCR
NON-FINAL ACTION WRITTEN
Oct 4, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 30, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 20, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 14, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 12, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 8, 2022 REPR